Objectives :This open prospective study wa:; performed in order to evaluate the efficacy and extrapyramidal adverse `~ effects of nemonapride in the schizophrenic patients, and was compared with one of typical antipsyciiotics, haloperidol ~´ and one of atypical antipsychotics, risperidone. ´´
Methods :Thirty male and female schizophrenic patients(DSM- IV) were treated for 12 weeks with haloperidol (n=10), risperidone(n=10) and nemonapride(n=10). The overall efficacy was assessed at baseline, 1st week, 2nd week, 4th week, 8th week, and 12th week by the Positive and Negative Syndrome Scale for Schizophrenia (PgNSS). Aldo the overall safety was assessed in the same time period by the Extrapyramidal Symptom Rating Scale(ESRS).
,´ ,;_
"Results :There were no significant differences in PANSS scores (total, positive, negative, and general psycho-pathology subscale) among haloperidol, risperidone, and nemonapride groups. Treatment responders, defined as;x
at least 20% reduction of baseline total PANSS score, were achieved by 8 patients(806) in haloperidol group, 10 ~~ -.~~, patients(100%) in risperidone group, and 8 patients(80%) in nemonapride group. And there were no significant
differences in ESRS total scores among haloperidol, risperidone, and nemonapride groups. Inter-group comparison among haloperidol, risperidone and nemonapride group, as assessed by the ESRS, revealed no significant differences in the shifts to the maximum score, 9.4(-!9.4), 6.2(8.4), and 11.3(8.1) respectively, and also revealed ,! no significant differences in the mean time reaching the maximum score, 4.5(4.5) week, 7.8(4.8) week, arid" ~` 4.6(4.4;1 week, respectivily.
Conclusion :There were no significant differences in the efficacy and extrapyramidal adverse effects among haloperidol, risperidone and nemonapride groups. These results suggest that nemonapride was as efficacious
|